NO20064830L - Sammensetning for fast farmasoytisk preparat av solifenacin eller salter derav - Google Patents

Sammensetning for fast farmasoytisk preparat av solifenacin eller salter derav

Info

Publication number
NO20064830L
NO20064830L NO20064830A NO20064830A NO20064830L NO 20064830 L NO20064830 L NO 20064830L NO 20064830 A NO20064830 A NO 20064830A NO 20064830 A NO20064830 A NO 20064830A NO 20064830 L NO20064830 L NO 20064830L
Authority
NO
Norway
Prior art keywords
solifenacin
composition
solid pharmaceutical
salt
compound
Prior art date
Application number
NO20064830A
Other languages
English (en)
Other versions
NO340020B1 (no
Inventor
Akio Sugihara
Takehiko Yasuji
Katsuhiro Masaki
Daisuke Murayama
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064830(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NO20064830L publication Critical patent/NO20064830L/no
Publication of NO340020B1 publication Critical patent/NO340020B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Et fast, farmasøytisk preparat av solifenacin eller et salt derav, hvori preparatet er stabilt og inhibert mot nedbrytning med tiden ved klinisk anvendelse. I et farmasøytisk preparat som inneholder solifenacin eller et salt derav, ble det vist at forbindelsen i amorf form var årsaken til den viktigste nedbrytning av medikamentet med tiden. Sammensetningen for et fast, farmasøytisk preparat av solifenacin eller et salt derav inneholder solifenacin eller et salt derav, begge i krystallinsk form, og innholdet av forbindelsen i amorf form ligger innenfor et område som ikke påvirker produktets stabilitet. Videre tilveiebringes en fremgangsmåte for fremstilling av sammensetningen og en medisinsk sammensetning for faste, farmasøytiske preparater som inneholder solifenacin og en forbindelse som inhiberer dannelsen av amorft materiale.
NO20064830A 2004-03-25 2006-10-24 Farmasøytisk tablett som omfatter en blanding som inneholder krystallinsk solifenacin eller et salt derav og en farmasøytisk eksipiens, hvor det er et lavt amorft innhold av solifenacin, samt fremgangsmåte for fremstilling derav. NO340020B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55602504P 2004-03-25 2004-03-25
US63838804P 2004-12-27 2004-12-27
PCT/JP2005/005377 WO2005092889A1 (ja) 2004-03-25 2005-03-24 ソリフェナシンまたはその塩の固形製剤用組成物

Publications (2)

Publication Number Publication Date
NO20064830L true NO20064830L (no) 2006-11-30
NO340020B1 NO340020B1 (no) 2017-02-27

Family

ID=35056127

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064830A NO340020B1 (no) 2004-03-25 2006-10-24 Farmasøytisk tablett som omfatter en blanding som inneholder krystallinsk solifenacin eller et salt derav og en farmasøytisk eksipiens, hvor det er et lavt amorft innhold av solifenacin, samt fremgangsmåte for fremstilling derav.

Country Status (19)

Country Link
US (2) US8039482B2 (no)
EP (2) EP1728791A4 (no)
JP (3) JP5168711B2 (no)
KR (5) KR101836467B1 (no)
AU (1) AU2005226357B2 (no)
BG (2) BG1639U1 (no)
BR (1) BRPI0509062A (no)
CA (1) CA2561167C (no)
CZ (2) CZ23090U1 (no)
DK (1) DK2156824T3 (no)
ES (1) ES2397307T3 (no)
IL (1) IL178249A (no)
MX (1) MXPA06010908A (no)
NO (1) NO340020B1 (no)
PL (1) PL2156824T3 (no)
PT (1) PT2156824E (no)
RU (1) RU2359670C2 (no)
SK (2) SK50222011U1 (no)
WO (1) WO2005092889A1 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
MXPA06010908A (es) 2004-03-25 2006-12-15 Astellas Pharma Inc Composicion para la preparacion farmaceutica solida de solifenacina o una sal de la misma.
AU2005320672B2 (en) * 2004-12-27 2011-01-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP1945636A2 (en) * 2006-08-03 2008-07-23 Teva Pharmaceutical Industries Ltd. Polymorphs of solifenacin intermediate
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
HUE031913T2 (en) 2007-12-07 2017-08-28 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2210595A1 (en) * 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
ES2609061T3 (es) 2009-02-27 2017-04-18 Krka, D.D., Novo Mesto Procedimiento para formar unas formas farmacéuticas orales sólidas de solifenacina y sus sales farmacéuticamente aceptables
WO2010113840A1 (ja) 2009-03-30 2010-10-07 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011137877A2 (en) 2010-05-07 2011-11-10 Zentiva K.S. A pharmaceutical composition containing solifenacin and a method of its manufacture
PH12012502132A1 (en) 2010-05-19 2013-02-04 Astellas Pharma Inc Pharmaceutical composition containing solifenacin
US8765785B2 (en) 2010-07-05 2014-07-01 Crystal Pharma, S.A.U. Solifenacin salts
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2500013B1 (en) 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
WO2012154774A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
MX355183B (es) 2012-01-25 2018-04-09 Vertex Pharma Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
TWI500223B (zh) * 2012-09-17 2015-09-11 Delta Electronics Inc Rj連接器的端子結構、應用其之rj連接器模組及rj連接器系統
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
HRP20210516T2 (hr) * 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
KR20150102852A (ko) * 2014-02-28 2015-09-08 대원제약주식회사 무정형 솔리페나신 또는 그의 염을 포함하는 안정성이 증가된 고체분산체 조성물 및 그 제조방법
JP2015189677A (ja) * 2014-03-27 2015-11-02 テバ製薬株式会社 ソリフェナシン非晶質体を含有する医薬組成物
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
MX2017008078A (es) * 2014-12-19 2017-09-28 Merck Sharp & Dohme Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
JP6639024B2 (ja) * 2016-04-08 2020-02-05 大原薬品工業株式会社 化学的な安定性を改善した、非晶質体ソリフェナシン含有製剤
KR20180003340A (ko) * 2016-06-30 2018-01-09 한미약품 주식회사 무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법
JP6805699B2 (ja) * 2016-10-04 2020-12-23 ニプロ株式会社 医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法
JP6733499B2 (ja) * 2016-11-01 2020-07-29 ニプロ株式会社 ソリフェナシン含有医薬組成物とその製造方法
JP6792418B2 (ja) * 2016-11-08 2020-11-25 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤の製造方法
WO2018154495A1 (en) 2017-02-24 2018-08-30 Ftf Pharma Private Limited Pharmaceutical composition of oral solution of muscarinic antagonist
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
EP4035660A1 (en) * 2017-10-17 2022-08-03 Synthon B.V. Tablets comprising tamsulosin and solifenacin
UY38137A (es) 2018-03-08 2019-07-31 Intas Third Party Sales 2005 S L Una forma de dosificación oral sólida farmacéutica de solifenacina
KR20200077268A (ko) 2018-12-20 2020-06-30 충북대학교 산학협력단 솔리페나신 타르타르산염의 구강 투여용 약학 제제로서의 용도
KR20210114271A (ko) 2020-03-10 2021-09-23 주식회사 종근당 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 함유하는 약제학적 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573140A (en) 1983-03-30 1986-02-25 Voicetek Corporation Method of and apparatus for voice communication storage and forwarding with simultaneous access to multiple users
US4870059A (en) * 1985-11-27 1989-09-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Dehydration of hydrous matter with anhydrous maltose
JPS62136240A (ja) 1985-12-11 1987-06-19 Hayashibara Biochem Lab Inc 脱水剤及びそれを用いる含水物の脱水方法
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
CA2052679C (en) 1990-08-30 1997-12-02 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (no) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
ZA938438B (en) 1992-11-17 1994-06-20 Sankyo Co Crystalline carbapenem derivative
WO1994020505A1 (en) 1993-03-12 1994-09-15 The Upjohn Company Crystalline ceftiofur free acid
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
JPH0971764A (ja) 1995-06-28 1997-03-18 Ajinomoto Co Inc 粉 体
JPH0971761A (ja) * 1995-07-06 1997-03-18 Yokohama Rubber Co Ltd:The 絶縁耐熱性接着剤およびその製造方法
JPH09110698A (ja) 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
DE19612131A1 (de) 1996-03-27 1998-01-22 Hoechst Ag Feste Arzneistoffzubereitung, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl) -anilid
HUP0002744A3 (en) 1997-01-06 2001-01-29 Pfizer Rapidly releasing and taste-masking pharmaceutical dosage form
ATE323467T1 (de) * 1997-07-25 2006-05-15 Alpex Pharma Sa Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
JP2002104968A (ja) * 2000-09-28 2002-04-10 Senju Pharmaceut Co Ltd 毛様体筋の緊張緩和剤
US20020119196A1 (en) 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
WO2002085335A1 (en) * 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
CA2447693A1 (en) * 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
ZA200309632B (en) 2001-07-10 2004-12-22 Yamanouchi Pharma Co Ltd Medicinal composition for treatment of interstitial cystitis.
KR20050005410A (ko) * 2002-02-19 2005-01-13 파마시아 코포레이션 요실금 치료용으로서의 시클로옥시게나제 저해제 및항무스카린제의 용도
JP4173670B2 (ja) * 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
DE10224107A1 (de) 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
CA2487899A1 (en) 2002-06-07 2003-12-18 Yamanouchi Pharmaceutical Co., Ltd. Overactive bladder treating drug
JP2004026675A (ja) 2002-06-21 2004-01-29 Lion Corp 咀嚼型医薬製剤用粒子、それを使用した咀嚼型医薬製剤、及び咀嚼型医薬製剤の不快味抑制方法
JP2006511494A (ja) * 2002-10-29 2006-04-06 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗ムスカリン剤としてのキヌクリジニウム誘導体
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
EP1492519B1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
EP1638537A1 (en) * 2003-07-01 2006-03-29 KRKA, tovarna zdravil, d.d., Novo mesto Tamsulosin core with a coating of polyvinylpyrrolidone and polyvinylacetate
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
EP1679066A4 (en) 2003-10-27 2011-06-22 Astellas Pharma Inc MEDICINAL COATING MICROPARTICLES FOR A MOUTH-DISABLE TABLET
EP1714965A4 (en) * 2004-02-09 2007-12-19 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACINE SUCCINATE
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
CA2560080A1 (en) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Solifenacin-containing composition
MXPA06010908A (es) 2004-03-25 2006-12-15 Astellas Pharma Inc Composicion para la preparacion farmaceutica solida de solifenacina o una sal de la misma.
AU2005320672B2 (en) * 2004-12-27 2011-01-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms

Also Published As

Publication number Publication date
US20080039516A1 (en) 2008-02-14
US20110065746A1 (en) 2011-03-17
JP5177156B2 (ja) 2013-04-03
KR101270908B1 (ko) 2013-06-03
DK2156824T3 (da) 2012-11-05
IL178249A (en) 2011-11-30
IL178249A0 (en) 2006-12-31
SK6199Y1 (sk) 2012-08-06
KR20120030597A (ko) 2012-03-28
JP2013040193A (ja) 2013-02-28
PL2156824T3 (pl) 2013-03-29
KR20070010132A (ko) 2007-01-22
US8039482B2 (en) 2011-10-18
WO2005092889A1 (ja) 2005-10-06
JP2010163442A (ja) 2010-07-29
CZ23090U1 (cs) 2011-12-19
AU2005226357A1 (en) 2005-10-06
NO340020B1 (no) 2017-02-27
KR101836467B1 (ko) 2018-03-08
JPWO2005092889A1 (ja) 2008-02-14
CZ23088U1 (cs) 2011-12-19
PT2156824E (pt) 2013-01-04
SK50202011U1 (sk) 2012-03-02
KR20110038189A (ko) 2011-04-13
SK50222011U1 (sk) 2012-10-02
KR101156406B1 (ko) 2012-06-13
CA2561167C (en) 2012-09-11
RU2359670C2 (ru) 2009-06-27
EP1728791A1 (en) 2006-12-06
KR20130041346A (ko) 2013-04-24
BG1638U1 (bg) 2012-12-28
AU2005226357B2 (en) 2010-07-01
MXPA06010908A (es) 2006-12-15
JP5168711B2 (ja) 2013-03-27
BG1639U1 (bg) 2012-12-28
EP2156824A1 (en) 2010-02-24
BRPI0509062A (pt) 2007-08-21
RU2006137565A (ru) 2008-04-27
EP2156824B1 (en) 2012-10-24
CA2561167A1 (en) 2005-10-06
KR20140146044A (ko) 2014-12-24
EP1728791A4 (en) 2008-12-10
ES2397307T3 (es) 2013-03-06

Similar Documents

Publication Publication Date Title
WO2008144730A3 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
EP1728791A4 (en) COMPOSITIONS FOR SOLID PHARMACEUTICAL PREPARATION OF SOLIFENACIN OR BZW. A SALT OF IT
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
WO2008089151A3 (en) High dose film compositions and methods of preparation
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
CN111295202B (zh) 治疗甲癣的外用制剂
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
JP2013540104A (ja) 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
CA2649022A1 (en) Cocrystal of c-glycoside derivative and l-proline
WO2009139576A3 (ko) 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
HK1042303A1 (zh) 新的化合物
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE9904413D0 (sv) Comminuted form
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same
US20190000847A1 (en) Therapeutic agent for a wound
PH12017502252A1 (en) Stable pharmaceutical composition for oral administration
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
HK1042493A1 (zh) 新的化合物

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees